Publikationen in Zusammenarbeit mit Forschern von GlaxoSmithKline (United Kingdom) (7)

2019

  1. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study

    HIV Research and Clinical Practice, Vol. 20, Núm. 4-5, pp. 111-122

2013

  1. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

    AIDS, Vol. 27, Núm. 11, pp. 1771-1778

  2. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

    The Lancet, Vol. 381, Núm. 9868, pp. 735-743

2009

  1. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): A randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance

    Journal of Antimicrobial Chemotherapy, Vol. 64, Núm. 2, pp. 398-410

  2. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks

    HIV Clinical Trials, Vol. 10, Núm. 2, pp. 76-87

2004

  1. A randomized study investigating the efficacy and safety of amprenavir in combination with low-dose ritonavir in protease inhibitor-experienced HIV-infected adults

    HIV Medicine, Vol. 5, Núm. 4, pp. 296-302

2002

  1. Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy

    Antiviral Therapy, Vol. 7, Núm. 1, pp. 43-51